TY - JOUR
T1 - Glioblastoma with oligodendroglioma component (GBM-O)
T2 - Molecular genetic and clinical characteristics
AU - Appin, Christina L.
AU - Gao, Jingjing
AU - Chisolm, Candace
AU - Torian, Mike
AU - Alexis, Dianne
AU - Vincentelli, Cristina
AU - Schniederjan, Matthew J.
AU - Hadjipanayis, Costas
AU - Olson, Jeffrey J.
AU - Hunter, Stephen
AU - Hao, Chunhai
AU - Brat, Daniel J.
PY - 2013/7
Y1 - 2013/7
N2 - Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM-Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation-specific polymerase chain reaction (PCR). GBM-Os accounted for 11.9% of all GBMs. GBM-Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM-Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM-O appeared to be associated with a younger age at presentation. Among patients with GBM-O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM-O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.
AB - Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM-Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation-specific polymerase chain reaction (PCR). GBM-Os accounted for 11.9% of all GBMs. GBM-Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM-Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM-O appeared to be associated with a younger age at presentation. Among patients with GBM-O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM-O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.
KW - IDH1 mutation
KW - LOH 1p 19q
KW - glioblastoma
KW - glioblastoma with oligodendroglioma component
KW - molecular characteristics
UR - http://www.scopus.com/inward/record.url?scp=84879225414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879225414&partnerID=8YFLogxK
U2 - 10.1111/bpa.12018
DO - 10.1111/bpa.12018
M3 - Article
C2 - 23289977
AN - SCOPUS:84879225414
SN - 1015-6305
VL - 23
SP - 454
EP - 461
JO - Brain Pathology
JF - Brain Pathology
IS - 4
ER -